Harnessing Microbial Recognition and Host Defense Responses To Fight Cancer
Manhattan BioSolutions is an emerging biotech company focused on the development of biologic therapies that target microbial recognition and inflammatory signaling pathways for the treatment of advanced, metastatic cancers. We develop innovative tumor-targeted drugs that selectively seek and destroy cancer cells while sparing healthy tissues
In the News
Scientific Platforms
Biologics
Developing novel biologics – mAbs & ADCs that target immuno-regulatory receptors overexpressed in tumors. The ADCs are designed to selectively eliminate cancer cells via multiple immune-mediated mechanisms
Synthetic Microbes
The sMIST (Synthetic Microbial Immune Stimulators) platform is based on genetically engineered microbes – “living drugs” that target mutated tumor antigens to induce innate and tumor-specific adaptive immunity
Get in touch !
If you are interested in exploring innate immunity and its translation into human therapies, or if your technology could advance the science, please contact us at ir@manhattanbiosolutions.com